Conducting a practice-based audit of Dianette® prescribing
An audit of co-cyprindiol (Dianette® Schering Health, UK) prescribing was conducted in January 2003 in response to the recommendations of the Committee on Safety of Medicines (CSM). The individual recommendations were based on epidemiological evidence that Dianette®, a combined oral contraceptive containing cyproterone acetate and ethinylestradiol, was associated with an increased risk of venous thromboembolism (VTE).
Dermatology in practice 2004; 12(1): 10–14
To continue reading this article, please sign in or register.